Early Detection Research Network


This biomarker is also known as:
  • LIG3,
  • FLJ90440,
  • LIG-3,
  • leucine-rich repeats and immunoglobulin-like domains 3,
  • LRIG3,
  • LIRG3,
  • leucine-rich repeats and immunoglobulin-like domains protein 3,
  • KIAA3016,


The LRIG3 protein is a widely expressed type I membrane protein. It contains three Ig-like C2-type (immunoglobulin-like) domains, 15 LRR (leucine-rich) repeats, 1 LRRCT domain, and 1 LRRNT domain.


There are no datasets associated with this biomarker.

QA State: Curated
Type: Protein

The following organs have data associated with this biomarker…


Phase: Two
QA State: Curated


Decreased expression of LRIG3 protein in glioblastoma cell lines resulted in increased proliferation and invasion, decreased apoptosis, and increased EGFR expression, leading to the hypothesis that LRIG is a tumor suppressor. A decreased level of LRIG was also seen in the serum of lung cancer patients compared to controls in the aptamer proteomic technology study (Ostroff et al, 2010).

Performance Comment

LRIG3 is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.